Most researchers seeking out CJC-1295 in Ulma rapidly learn that local retail options are nearly impossible to find. This matters because CJC-1295 quality varies dramatically across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor determines everything about the product. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. Use this guide to assess sourcing options methodically — the quality evaluation approach outlined here are universal across all research contexts.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Ulma comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Quality CJC-1295 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Vendors who do are operating transparently. Mass spectrometry in the COA verifies that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone provides no identity confirmation. Negative indicators in CJC-1295 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that omit endotoxin testing. Keep lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Ulma
COA-verified · International tracking · Research grade
All use of CJC-1295 in Ulma or anywhere constitutes research use — this compound is not approved for clinical human use, and all handling should follow research laboratory protocols. Temperature excursions — even brief warming above recommended storage temperature — can compromise product integrity without visible changes; always maintain cold chain and work with cold-shipped material. Quality CJC-1295 sourcing is not separable from research safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that rigorous vendor evaluation eliminates. For any individual considering CJC-1295 outside a formal research context: consult a qualified physician — this compound is not approved for human use and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
